Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
acetylcholine (1) 1
acetylcholine-receptor (1) 1
activities of daily living (1) 1
adult (1) 1
adult; aged; antibodies, monoclonal, humanized; autoantibodies; double-blind method; drug resistance; female; humans; male; middle aged; myasthenia gravis; receptors, cholinergic; outcome assessment; severity of illness index; neurology (1) 1
aged (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - pharmacology (1) 1
autoantibodies - blood (1) 1
clinical neurology (1) 1
complement inhibitor eculizumab (1) 1
daily living profile (1) 1
double-blind method (1) 1
drug resistance (1) 1
end-plate (1) 1
endplate (1) 1
female (1) 1
humans (1) 1
immunoglobulins (1) 1
index medicus (1) 1
localization (1) 1
male (1) 1
middle aged (1) 1
myasthenia (1) 1
myasthenia gravis (1) 1
myasthenia gravis - blood (1) 1
myasthenia gravis - drug therapy (1) 1
myasthenia gravis - physiopathology (1) 1
neurology (1) 1
neuromuscular junctions (1) 1
outcome assessment (1) 1
paroxysmal-nocturnal hemoglobinuria (1) 1
patients (1) 1
receptors, cholinergic - immunology (1) 1
severity of illness index (1) 1
studies (1) 1
transplants & implants (1) 1
trial (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
by Howard, James F and Utsugisawa, Kimiaki and Benatar, Michael and Murai, Hiroyuki and Barohn, Richard J and Illa, Isabel and Jacob, Saiju and Vissing, John and Burns, Ted M and Kissel, John T and Muppidi, Srikanth and Nowak, Richard J and O'Brien, Fanny and Wang, Jing-Jing and Mantegazza, Renato and Mazia, Claudio Gabriel and Wilken, Miguel and Ortea, Carolina and Saba, Juliet and Rugiero, Marcelo and Bettini, Mariela and Vidal, Gonzalo and Vidal, Nuria and Garcia, Rebekah and Garcia, Sonia and Garcia, Alejandra Dalila and Lamont, Phillipa and Leong, Wai-Kuen and Boterhoven, Heidi and Fyfe, Beverly and Roberts, Leslie and Jasinarachchi, Mahi and Willlems, Natasha and Wanschitz, Julia and Löscher, Wolfgang and De Bleecker, Jan and Van den Abeele, Guy and de Koning, Kathy and De Mey, Katrien and Mercelis, Rudy and Wagemaekers, Linda and Mahieu, Delphine and Van Damme, Philip and Smetcoren, Charlotte and Stevens, Olivier and Verjans, Sarah and D'Hondt, Ann and Tilkin, Petra and Alves de Siqueira Carvalho, Alzira and Hasan, Rosa and Dias Brockhausen, Igor and Feder, David and Ambrosio, Daniel and Melo, Ana Paula and Rocha, Rosana and Rosa, Bruno and Veiga, Thabata and Augusto da Silva, Luiz and Gonçalves Geraldo, Jordana and da Penha Morita Ananias, Maria and Nogueira Coelho, Erica and Paiva, Gabriel and Pozo, Marina and Prando, Natalia and Dada Martineli Torres, Debora and Fernanda Butinhao, Cristiani and Coelho, Erica and Renata Cubas Volpe, Luciana and Duran, Gustavo and Gomes da Silva, Tamires Cristina and Otavio Maia Gonçalves, Luiz and Pazetto, Lucas Eduardo and Souza Duca, Luciana and Suriane Fialho, Tomás Augusto and Gheller Friedrich, Maurício André and Guerreiro, Alexandre and Mohr, Henrique and Pereira Martins, Maurer and da Cruz Pacheco, Daiane and Macagnan, Ana Paula and de Cassia Santos, Aline and Bulle Oliveira, Acary Souza and Amaral de Andrade, Ana Carolina and Annes, Marcelo and Cavalcante Lino, Valeria and Pinto, Wladimir and Miranda, Carolina and Carrara, Fernanda and Souza, Iandra and Genge, Angela and Massie, Rami and Campbell, Natasha and Bril, Vera and Katzberg, Hans and Soltani, Mehran and Ng, Eduardo and Siddiqi, Zaeem and Phan, Celile and Blackmore, Derrick and Vohanka, Stanislav and ... and REGAIN Study Grp and REGAIN Study Group
The Lancet Neurology, ISSN 1474-4422, 12/2017, Volume 16, Issue 12, pp. 976 - 986
Complement is likely to have a role in refractory generalised myasthenia gravis, but no approved therapies specifically target this system. Results from a... 
TRIAL | ENDPLATE | LOCALIZATION | COMPLEMENT INHIBITOR ECULIZUMAB | DAILY LIVING PROFILE | PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA | ACETYLCHOLINE-RECEPTOR | END-PLATE | CLINICAL NEUROLOGY | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Double-Blind Method | Myasthenia Gravis - blood | Outcome Assessment (Health Care) | Autoantibodies - blood | Humans | Middle Aged | Male | Antibodies, Monoclonal, Humanized - administration & dosage | Myasthenia Gravis - physiopathology | Antibodies, Monoclonal, Humanized - pharmacology | Adult | Female | Receptors, Cholinergic - immunology | Aged | Myasthenia Gravis - drug therapy | Drug Resistance | Studies | Neurology | Immunoglobulins | Activities of daily living | Myasthenia gravis | Transplants & implants | Neuromuscular junctions | Acetylcholine | Myasthenia | Patients | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.